The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Tolga Tanguler, insider at Alnylam Pharmaceuticals

Tolga Tanguler Insider Information

Tolga Tanguler joined Alnylam in January 2021 and has over 20 years of global biopharmaceutical experience in a variety of marketing and commercial roles. He has worked across multiple geographies including the U.S., Europe, and emerging markets and in a broad range of small and large disease therapy areas.

Prior to joining Alnylam, Tolga served for two years as Senior Vice President and Head of Alexion U.S., where he led an organization of 700 colleagues across sales, market access, marketing, operations, and patient services. Before Alexion, he spent the majority of his career at Pfizer serving in roles of increasing responsibility, most recently as Regional President, North America for Rare Diseases and prior to that as Global Vice President and Alliance Co-Head, Eliquis, as well as and serving as a country manager of Denmark and Iceland during his tenure.

Tolga received his Bachelor of Science in Finance and Economics from Istanbul University in Turkey and his MBA in Marketing and Supply Chain Management from Michigan State University, as well as a post graduate certificate in Marketing from the University of California, Santa Barbara.

What is Tolga Tanguler's net worth?

The estimated net worth of Tolga Tanguler is at least $848,242.46 as of August 3rd, 2022. Mr. Tanguler owns 3,629 shares of Alnylam Pharmaceuticals stock worth more than $848,242 as of August 10th. This net worth approximation does not reflect any other assets that Mr. Tanguler may own. Learn More about Tolga Tanguler's net worth.

How do I contact Tolga Tanguler?

The corporate mailing address for Mr. Tanguler and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected] Learn More on Tolga Tanguler's contact information.

Has Tolga Tanguler been buying or selling shares of Alnylam Pharmaceuticals?

During the past quarter, Tolga Tanguler has sold $1,033,072.56 in Alnylam Pharmaceuticals stock. Most recently, Tolga Tanguler sold 1,841 shares of the business's stock in a transaction on Friday, August 5th. The shares were sold at an average price of $218.16, for a transaction totalling $401,632.56. Learn More on Tolga Tanguler's trading history.

Who are Alnylam Pharmaceuticals' active insiders?

Alnylam Pharmaceuticals' insider roster includes Jeffrey Dunn (CEO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Alnylam Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 91,185 shares worth more than $16,759,341.21. The most recent insider tranaction occured on August, 5th when EVP Tolga Tanguler sold 1,841 shares worth more than $401,632.56. Insiders at Alnylam Pharmaceuticals own 1.4 % of the company. Learn More about insider trades at Alnylam Pharmaceuticals.

Information on this page was last updated on 8/5/2022.

Tolga Tanguler Insider Trading History at Alnylam Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/5/2022Sell1,841$218.16$401,632.56View SEC Filing Icon  
8/3/2022Sell1,754$210.00$368,340.003,629View SEC Filing Icon  
7/5/2022Sell1,754$150.00$263,100.001,754View SEC Filing Icon  
See Full Table

Tolga Tanguler Buying and Selling Activity at Alnylam Pharmaceuticals

This chart shows Tolga Tanguler's buying and selling at Alnylam Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $232.00
Low: $224.40
High: $233.88

50 Day Range

MA: $149.23
Low: $123.05
High: $230.74

2 Week Range

Now: $232.00
Low: $117.58
High: $233.88


969,528 shs

Average Volume

900,702 shs

Market Capitalization

$27.85 billion

P/E Ratio


Dividend Yield



A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.